[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346766-105":59,"doc-detail-346766-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","across-the-social-network-of-the-gut-bacterial-fungal-and-viral-determinants-of-checkpoint-inhibitor-efficacy-and-toxicity","Across the Social Network of the Gut - Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity","","Recent findings indicate that the gut microbiome affects cancer outcomes, including how patients respond to immune checkpoint inhibitors (ICIs) and the risk of immune-related adverse events. While early work emphasized gut bacteria, the microbiome also comprises the bacteriome, virome, and mycobiome, which can shape host immunity. Multi-omics studies across cohorts associate distinct fungal and viral patterns with ICI responders versus non-responders. Mechanistic links connect dysbiosis, immune sensing, and changes in beneficial or pathobiont populations to ICI efficacy and toxicity, including ICI-induced colitis. Strategies to modulate the microbiome may enhance benefit while reducing harm, supporting new biomarkers and therapeutic adjuvants in cancer immunotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/across-the-social-network-of-the-gut-bacterial-fungal-and-viral-determinants-of-checkpoint-inhibitor-efficacy-and-toxicity/346766/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/across-the-social-network-of-the-gut-bacterial-fungal-and-viral-determinants-of-checkpoint-inhibitor-efficacy-and-toxicity/346766.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does the gut microbiome influence immune checkpoint inhibitor outcomes?","Question",{"text":113,"@type":114},"The gut microbiome modulates host immunity, affecting both response to immune checkpoint inhibitors (ICIs) and the likelihood of immune-related toxicities. Multi-omics evidence links distinct microbial patterns with responders versus non-responders.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What roles do fungi and viruses play alongside gut bacteria in ICI efficacy and toxicity?",{"text":118,"@type":114},"Fungal populations may shape anti-cancer immunity through inflammatory or tolerogenic pathways, while viral components can stimulate innate immune sensors that support tumor surveillance. Dysbiosis involving pathobionts and reduced beneficial microbes is associated with serious irAEs such as ICI-induced colitis.",{"name":120,"@type":111,"acceptedAnswer":121},"What strategies does the review discuss to modulate the microbiome?",{"text":122,"@type":114},"The review discusses mechanisms connecting microbes to anti-tumor immunity, summarizes human studies linking microbiome profiles to ICI outcomes, and explores approaches to modulate the microbiome to improve efficacy and reduce toxicity, potentially enabling new biomarkers and therapeutic adjuvants.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346766,1790470986,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Review  \nAcross the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity  \nAndreea Laura Antohi 1, Andreea Daria Gheorghiă 1, Octavian Andronic 2,3, Gratiela Gradisteanu Pircalabioru 4,5,6, * and Andreea-Ramona Treteanu 2,3  \nAcademic Editor: Carmine Stolfi  \nReceived: 31 December 2025  \nRevised: 21 February 2026  \nAccepted: 5 March 2026  \nPublished: 10 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street,  \n700115 Iasi, Romania; [antohi.andreea31@yahoo.com](antohi.andreea31@yahoo.com) (A.L.A.); [andreea.gheorghita05@gmail.com](andreea.gheorghita05@gmail.com) (A.D.G.)  \n2 Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street,  \n020021 Bucharest, Romania; octavian.andronic@umfcd.ro (O.A.);  \n[andreea-ramona.treteanu0720@stud.umfcd.ro](andreea-ramona.treteanu0720@stud.umfcd.ro) (A.-R.T.)  \n3 Innovation and eHealth Center, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania  \n4 Department of Botany and Microbiology, Faculty of Biology, University of Bucharest,  \n030018 Bucharest, Romania  \n5 Research Institute of University of Bucharest (ICUB), University of Bucharest, 050095 Bucharest, Romania  \n6 eBio-Hub Centre of Excellence in Bioengineering, National University of Science and Technology Politehnica Bucharest, 060042 Bucharest, Romania  \n* Correspondence: [gratiela.gradisteanu@icub.unibuc.ro](gratiela.gradisteanu@icub.unibuc.ro)  \nAbstract  \nRecent findings suggest that the gut microbiome significantly influences cancer outcomes, including responses to immune checkpoint inhibitor (ICI) treatments. Although early research focused on gut bacteria, it is now understood that the microbiome includes abacteriome, virome, and mycobiome, all of which can modulate host immunity. Some commensal bacteria enhance anti-tumor immune responses and improve ICI efficacy, as demonstrated in both mice and patients. Fecal microbiota transplants (FMT) from patients responding to ICI have successfully reversed resistance in certain non-responders. In addition to bacteria, gut fungi and viruses are gaining attention as further factors influencing ICI effectiveness and toxicity. Recent multi-omics studies across cancer cohorts show that fungal and viral populations in the gut vary between ICI responders and nonresponders. Commensal fungi may shape anti-cancer immunity by inducing inflammatory or tolerogenic pathways, while viral components can stimulate innate immune sensors that promote tumor surveillance. On the other hand, gut dysbiosis marked by expansion of pathobionts (including opportunistic fungi) and reduction in beneficial microbes is linked to serious immune-related adverse events (irAEs) such as ICI-induced colitis. This review discusses the multi-kingdom gut microbiome–bacteria, fungi, and viruses–and their interactions with the immune system in cancer therapy. We emphasize known mechanisms linking these microbes to anti-tumor immunity, overview human studies associating gut microbiome profiles with ICI outcomes and explore strategies to modulate the microbiome to enhance ICI efficacy while reducing toxicity. Understanding and utilizing the gut mycobiome and virome in conjunction with the bacteriome could pave the way for new biomarkers and therapeutic adjuvants in cancer immunotherapy.  \nKeywords: mycobiome; virome; gut microbiome; immune checkpoint inhibitor; fecal microbiota transplant; cancer  \n1. Introduction  \nCancer continues to be a significant global health challenge. The most recent GLOBOCAN report estimates approximately 20 million new cancer cases and 9.7 million deaths in 2022, with around 53.5 million people livi","cbCaifPp3fKeF6ol","https://ap.wps.com/l/cbCaifPp3fKeF6ol","pdf",3182225,39,"English","# Introduction\n## Cancer burden and need for improved therapies\n## Immuno-oncology and treatment modalities\n## Immune checkpoint inhibitors: response variability and toxicity","[{\"question\":\"How does the gut microbiome influence immune checkpoint inhibitor outcomes?\",\"answer\":\"The gut microbiome modulates host immunity, affecting both response to immune checkpoint inhibitors (ICIs) and the likelihood of immune-related toxicities. Multi-omics evidence links distinct microbial patterns with responders versus non-responders.\"},{\"question\":\"What roles do fungi and viruses play alongside gut bacteria in ICI efficacy and toxicity?\",\"answer\":\"Fungal populations may shape anti-cancer immunity through inflammatory or tolerogenic pathways, while viral components can stimulate innate immune sensors that support tumor surveillance. Dysbiosis involving pathobionts and reduced beneficial microbes is associated with serious irAEs such as ICI-induced colitis.\"},{\"question\":\"What strategies does the review discuss to modulate the microbiome?\",\"answer\":\"The review discusses mechanisms connecting microbes to anti-tumor immunity, summarizes human studies linking microbiome profiles to ICI outcomes, and explores approaches to modulate the microbiome to improve efficacy and reduce toxicity, potentially enabling new biomarkers and therapeutic adjuvants.\"}]","Across the Social Network of the Gut - Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity | PDF",1790062662,98,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/568a03ea1b3f1373d463845401c2ef48.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5206126ca913b379def1f76c0e8edd83.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c1c3ab5b7a48a4b6b02ebc6da60d96e.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61f18ea8465241c044a155526a2462f7.webp",980,1385]